Vickers Venture leads $4.3m funding in UK-based biopharma firm SiSaf

Decheng Capital
An automated machine works on purification of potential hepatitis C virus drug candidate at the Gilead Sciences Inc. lab in Foster City, California, U.S., on Wednesday, Feb. 8, 2012. Photographer: David Paul Morris/Bloomberg

Singapore’s Vickers Venture Partners has led a $4.3-million interim funding round for UK-based biopharmaceutical company SiSaf, according to an official statement.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Should your colleagues be reading this article too? Contact us for corporate subscriptions at subs@dealstreetasia.com.